Fundraising Fox

Bioheng

4 known investors

Imviva is a clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for oncology and autoimmune diseases. The company focuses on creating safer, more effective off-the-shelf cell therapies designed to improve patient access and outcomes in regenerative medicine.

BiotechDeep TechHealthtechMedical Devices

Founders & leadership

JR
Jiangtao RenChief Scientific Officer
LH
Lu HanChief Executive Officer
YN
Yajin NiChief Technology Officer
JD
Jan DavidsonChief Medical Officer

Investors · 4

Decheng Capital✓ verifiedMenlo Park
GL Venturesreported · 2 sourcesBeijing
Hillhouse CapitalreportedChangyang · $2.9M – $220M
Shenzhen Capital Groupreported · 2 sourcesShenzhen · $1.5M – $156M

In the news

Sen. Rick Scott Calls for Review of CCP Involvement in U.S. Clinical Trials and Drug Approvalsrickscott.senate.gov · Mar 2026Bioheng Biotech Raises $80M in Series B Financing - FinSMEsfinsmes.com · Apr 2021Bioheng Biotech Raised $80 million in Series B Financing to Advance Allogeneic Immuno-Cell Therapiesprnewswire.com · Mar 2021BioCentury - Decheng backs Nanjing Bioheng in series Abiocentury.com · Feb 2019Trusted Insight | Chinese Biotech Start-up Bioheng Raises $15M Series A Round – China Money Network | Investment News | Trusted Insight Platformthetrustedinsight.com · Feb 2019

Frequently asked questions

What does Bioheng do?
Imviva is a clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for oncology and autoimmune diseases. The company focuses on creating safer, more effective off-the-shelf cell therapies designed to improve patient access and outcomes in regenerative medicine.
Who are Bioheng's investors?
Bioheng's investors include Decheng Capital, GL Ventures, Hillhouse Capital, Shenzhen Capital Group.